As a result of the stock exchange release published on 13 April 2026 at 9:30 a.m. (EEST) and the acquisition announced therein, Revenio Group Corporation has decided to cancel the Annual General Meeting 2026 that was convened to be held on Wednesday, 15 April 2026 at 4:00 p.m. (EEST).

The announced acquisition is subject to certain resolutions to be adopted by the General Meeting. The Company intends to submit these resolutions for approval, with the matters addressed at the Annual General Meeting.

The Board of Directors of Revenio Group Corporation will convene a new Annual General Meeting 2026 during the course of this week.

For further information, please contact
CEO Jouni Toijala, tel. +358 484 0085
jouni.toijala@revenio.fi

Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Main media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, microperimeters, and perimeters as well as software solutions under the iCare brand.

In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.